Close Menu

Bradley Cole

Dec 10, 2018

Castle Biosciences announced Bradley Cole has been appointed to its board. Cole is the CFO of Genomic Health and has more than 30 years of experience in finance and operations in the diagnostics and life sciences industries. He also has served as COO of Genomic Health. Prior to joining the firm, he was VP of finance and business development for the endovascular solutions group at Guiidant, and was VP and GM of vascular surgery business unit of Guidant. 

More Like This

Dec 03, 2020

Infinity Biologix: Amit Bhalla

Infinity Biologix  has appointed Amit Bhalla as its vice president and CFO. He will lead the company's financial operations as it enters its next phase of growth after spinning out from Rutgers University in August. IBX is a central lab that provides sample collection and processing, storage, analytical services, and scientific and technical support. It received Emergency Use Authorization from the US Food and Drug Administration for its saliva-based test for detecting SARS-CoV-2 in April.

Balla joins the firm after more than 20 years of experience on Wall Street and in the healthcare industry. He was most recently senior healthcare analyst at Lord, Abbett and previously had senior roles at Becton Dickinson, Citigroup, Morgan Stanley, and Johnson & Johnson.

Dec 01, 2020

Diadem: Tamas Bartfai

Alzheimer's disease test developer Diadem has named Tamas Bartfai, a neuroscientist and Alzheimer's disease researcher, as chair of its medical advisory board.

Bartfai is an international expert in the development of drugs targeting neurological diseases, including Alzheimer’s disease, the firm said.

In the past, he was a professor, chairman of molecular and integrative neurosciences, and director at the Dorris Neuroscience Center at the Scripps Research Institute, and an adjunct professor at Stockholm University, the University of Oxford, and the University of Pennsylvania.

Bartfai has served as a drug development senior executive or consultant to pharmaceutical companies, including AstraZeneca, Roche, Novartis, and Pfizer. He has also been a consultant to biotech venture capitalists and helped launch a number of biotech startups.

Nov 25, 2020

Interpace Biosciences: Thomas Burnell, Jack Stover

Interpace Biosciences said that current President and CEO Jack Stover will retire effective Dec. 31, 2020, and will be replaced as president and CEO by Thomas Burnell. Stover will also step down from the company's board of directors once Burnell joins the company and is appointed to the board, but will serve as an advisor to Interpace through the middle of 2021 to support the transition.

Burnell has previously served as president and CEO of Boston Heart Diagnostics, Viracor-IBT Laboratories, and Eurofins Scientific. He has also previously held leadership roles with companies such as Elite One Source, Nebraska Heart Institute, and most recently the Pioneer Heart Institute.

Nov 25, 2020

Enzo Biochem: Ian Walters

Ian Walters has been appointed to the board of directors of Enzo Biochem. He is the CEO and director of Portage Biotech, a biopharmaceutical firm developing immuno-oncology treatments. Previously, he was executive director of global oncology clinical research and business development at Bristol-Myers Squibb and medical director at Millennium Pharmaceuticals. Walters holds an MBA from the Wharton School of the University of Pennsylvania and an MD from Albert Einstein College of Medicine.

Nov 23, 2020

Thermo Fisher Scientific: Alexandra Keith

Alexandra Keith has been elected to the board of directors of Thermo Fisher Scientific. She is the CEO of Procter & Gamble's global beauty business and a member of P&G's global leadership council. Over the past 30 years, she has served in a variety of roles at P&G, including in manufacturing, logistics, communications, and product innovation.

Nov 19, 2020

Icahn School of Medicine at Mount Sinai: Alison Goate

Alison Goate has been named chair of the department of genetics and genomics sciences at the Icahn School of Medicine at Mount Sinai, effective Jan. 1, 2021.

Goate is the Willard T.C. Johnson research professor of neurogenetics and a professor of genetics and genomic science, neuroscience, and neurology. Her research focuses on genetic risk factors of neurodegenerative diseases, including Alzheimer's disease and frontotemporal dementia.

She came to Mount Sinai in 2015 as founding director of the Ronald M. Loeb Center for Alzheimer's Disease and is a member of the National Academy of Medicine and a fellow of the American Association for the Advancement of Science. Goate holds a doctorate from the University of Oxford.

Nov 19, 2020

Specific Diagnostics: Jeff Holman

Specific Diagnostics this week said that it has named Jeff Holman VP of global marketing. Holman most recently served as head of sales for the Core Laboratory vertical for Roche Diagnostics. He will lead all marketing and branding activities related to Specific's Reveal System and market launch in Europe, and subsequent launch of the rapid antimicrobial susceptibility testing system in the US, the firm said.

Nov 19, 2020

Natera: Monica Bertagnolli

Monica Bertagnolli has been appointed to the board of directors of Natera. She is a professor of surgery at Harvard Medical School and associate surgeon in the division of surgical oncology at Brigham and Women's Hospital and Dana-Farber Cancer Institute. In addition, she is the CEO of Alliance Foundation Trial, a nonprofit organization that conducts international cancer clinical trials, as well as VP of the Coalition of Cancer Cooperative Groups. Bertagnolli holds an undergraduate degree in engineering from Princeton University and a medical degree from the University of Utah College of Medicine.

Nov 18, 2020

Quanterix: William Geist

Quanterix has named William Geist as chief operating officer. Geist most recently served as vice president and general manager for two of Thermo Fisher Scientific's protein and cell analysis and qPCR business units. He also held a key leadership role in Thermo Fisher's COVID-19 task force in its biosciences division. Prior to this, Geist held numerous sales, marketing, and business development leadership roles including vice president of sales, marketing, and business development at Qiagen's Quanta BioSciences. He holds a BA in biology from Dartmouth College.

Nov 17, 2020

Day Zero Diagnostics: Dekel Gelbman, Robin Patel, Sally Hojvat

Day Zero Diagnostics has appointed Dekel Gelbman as senior VP of business development and strategy, Robin Patel as a member of its scientific advisory board, and Sally Hojvat as a regulatory strategy advisor.

Gelbman joins the company from FDNA, where he was the founding CEO. Before that, he was a corporate and transactional attorney in Israel and the US.

Patel is the director of the infectious diseases research laboratory and co-director of the clinical bacteriology laboratory at the Mayo Clinic.

Hojvat is a senior consultant at Partners in Diagnostics. Prior to that, she was the director of the division of microbiology devices at the Center for Devices and Radiological Health at the US Food and Drug Administration.

Nov 17, 2020

Veracyte: John Hanna, Morten Frost

Veracyte has appointed John Hanna as its general manager of endocrinology, breast cancer, and lymphoma; and Morten Frost as its general manager of pulmonology. The firm has established the general manager structure as part of its plans for global expansion.

Hanna currently serves as Veracyte's chief commercial officer. Prior to Veracyte, Frost most recently held the role of head of global marketing for pathology and companion diagnostics at Agilent Technologies.

Nov 17, 2020

Inivata: Alan Schafer

Inivata has appointed Alan Schafer as its chief technology officer. Schafer previously served as CEO of 14M Genomics, a cancer molecular diagnostic firm. Prior to 14M Genomics, he served as CEO of Population Genetics. He has also served as global VP of technology development at GlaxoSmithKline and VP of genetics at Incyte. 

Nov 13, 2020

Centogene: Jonathan Sheldon

Jonathan Sheldon has been nominated as a member of the supervisory board of Centogene. He will serve as an interim member with immediate effect until his confirmation at an upcoming shareholder meeting. Sheldon is senior VP of the digital insights business area at Qiagen and has led Qiagen's Digital Insights global business since 2018. Prior to this, he was global VP at Oracle Health Sciences.

Nov 11, 2020

Unilabs: Victoria Bell

Unilabs has appointed Victoria Bell its group chief financial officer ad interim, replacing Andrew Derodra who has left the Geneva-based diagnostics services provider for personal reasons. Bell has held senior roles in companies such as Centrient Pharmaceuticals, Wittur Group, JP Morgan, and Société Générale.                     

Nov 11, 2020

Magnolia Medical Technologies: Gary Doern

Blood sample collection device developer Magnolia Medical Technologies has appointed Gary Doern to its medical and scientific advisory board. He is professor emeritus of pathology at the University of Iowa Carver College of Medicine. His leadership roles include head of the American Board of Medical Microbiology, and chair of the clinical microbiology division of the American Society for Microbiology. Doern was also editor in chief of the Journal of Clinical Microbiology.